Summary~Mutation of the p53 gene is reported to be of prognostic importance in colorectal carcinomas. Immunohistochemical staining of the accumulated p53 gene product may be a simple alternative for p53 mutation analysis. Previous studies addressing the prognostic importance of p53 expression. however, yielded contradictory results. Therefore, we evaluated the importance of p53 expression as a marker for long-term prognosis in a well-characterised study population of 109 colorectal carcinomas. After antigen retrieval with target unmasking fluid (TUF). immunostaining of p53 was performed with both monoclonal antibody D07 and polyclonal antibody CMI. Objective quantification of the p53 signal was assessed by a computerised image analyser. p53 expression was higher in non-mucinous tumours than in mucinous tumours (p53 labelling index = 30% and 17% respectively, P = 0.05), and in metastatic tumours compared with non-metastatic tumours (p53 labelling index = 37% and 22% respectively, P = 0.05 Lane, 1992; Levine, 1992a Levine, , 1992b Oren, 1992; Vogelstein and Kinzler, 1992) . It is located on the short arm of chromosome 17 in the region 17pl3 and encodes a 53 kDa nuclear phosphoprotein that serves as a transcription factor El-Deiry et al., 1993). The p53 protein indirectly regulates cell growth and inhibits cells with mutagenic damage from entering the S-phase by arresting the cell cycle in GI, during which DNA repair can proceed.
The p53-suppressor gene is the most frequently altered gene in solid human malignancies (reviewed in Lane, 1992; Levine, 1992a Levine, , 1992b Oren, 1992; Vogelstein and Kinzler, 1992) . It is located on the short arm of chromosome 17 in the region 17pl3 and encodes a 53 kDa nuclear phosphoprotein that serves as a transcription factor El-Deiry et al., 1993) . The p53 protein indirectly regulates cell growth and inhibits cells with mutagenic damage from entering the S-phase by arresting the cell cycle in GI, during which DNA repair can proceed.
In colorectal cancer, p53 mutations are frequently accompanied by allelic loss of 17p (Baker et al., 1989; Rodrigues et al., 1990) . Both p53 mutations and allelic deletion of 17p occur late in tumour progression (Baker et al., 1990) and are reported to have prognostic value after surgery (Kern et al., 1989; Laurent-Puig et al., 1992; Offerhaus et al., 1992; Hamelin et al., 1994) . However, both detection of p53 mutations at the DNA level and detection of allelic deletion of 17p by restriction fragment length polymorphism (RFLP) analysis are cumbersome procedures and therefore not feasible in routine diagnosis.
Recent reports describe a strong relation between p53 gene mutations and mutant p53 protein expression (Rodrigues et al., 1990; de Angelis et al., 1993; Baas et al., 1994) . The mutant p53 protein is characterised by a conformational change resulting in prolonged half-life and stability, enabling its detection by routine immunohistochemical (IHC) techniques (Finlay et al., 1988) . Therefore, immunostaining of the p53 protein may be an important surrogate test for p53 mutation analysis.
In solid neoplasms including carcinomas of the breast (Barnes et al., 1993) , stomach (Martin et al., 1992; Starzynska et al., 1992) , lung (Quinlan et al., 1992) , ovary (Bosanr et al., 1993) and pancreas (DiGuiseppe et al., 1994) , p53 expression has been correlated with shortened survival. In colorectal carcinomas, however, a correlation between survival and nuclear p53 expression has not been consistently observed (Scott et al., 1991; Remvikos et al., 1992; Starzynska et (Baas et al.. 1994 (Bloem. 1983; Offerhaus et al., 1991) . For (Muklai et al., 1980; Muller et al., 1989; Offerhaus et al., 1991) .
Follow-up was obtained through physician contact and ended on 30 September 1993.
Immunohistochemistry for p53
On 109 paraffin-embedded specimens, routine immunostaining was performed as reported previously (Baas et al., 1994) (Baas et al., 1994) . Further saining was with the streptavdin-horseradish peroxidase (HRP)-ABC method (Vectastain, Vector Laboratories, Burlingame, CA, USA), and the chromagen was diaminobenzidine (DAB). Nulear counterstainmg was performed with methyl green, enabing p53 protein quantification by an image analyser (Baas et al., 1994) . Staining was controlled by omission of the primary antibody.
Image anatysis
The CAS 200 image analysis system consit of a conventional microscope with mounted television camera which is linked to a computer and colour monitor. The ER/PR software program enabled measurement of the total area of positive nulcear staining in any selected microscopic field, while the methyl green nuclear counterstain enabled measurement of the total nuclear area. The ratio expressed as p53 labelling index (LI) gave an objective value for the percentage of positive-staining nuclei. Baseline was set on p53-negative normal mucosa. Negative stromal ekments were controlled for by computing the mean p53 LI for each slide in at least five representative fields at 400 x magification, containing between 100 and 250 tumour nuclei (Baas et al., 1994) .
Statistical analysis
Statistical analysis was performed with JMP software (SAS Institute, Cary, NC, USA). For survival analysis p53 expression was divided into three groups: (1) no nuclear p53 expression (LI<1l%), (2) low nuclear p53 expression (LI 1-30%), and (3) high nuclear p53 expression (LI > 30%). This tripartition is based on the results of previous studies by our group (Baas et al., 1994 Figure lb) and grade of differentiation reained significnt. The amount of p53 expression in carcinomas showed a tendency towards an association with patient survival (P = 0.08), but the pattern of this relationship is difficult to interpret: the highest and lowest p53 categories showed the poorest survival, whereas the intermediate p53 category showed the best prognosis (Figure ic) .
In the complete cohort, multivanate analysis showed that only Dukes' stage (P = <0.001) and differentiation grade (P = 0.01) were independent markers for prognosis. These parameters were also independent predictors of prognosis in the smaler p53-tested cohort (Dukes' stage, P = 0.02; differentiation grade, P = 0.05) ( Table III) .
The prognosis after seemingly curative resection of colorectal carcinoma depends largely on the absence or presence of occult metastases, often accounting for mortality. Prediction of outcome is currently based mainly on the stage of colorectal carcinoma at time of resection. However, patients with tumours of the same stage often show dramatically different outcome. Therefore, more specific prognostic markers would provide a rationale to adjust different therapeutic approaches.
Alterations of the p53 tumour-suppressor gene are potentially such a marker (Hamelin et al., 1994) , and immunostaining of the p53 protein product could be a valuable test for p53 gene alterations (Rodrigues et al., 1990; de Angels et al., 1993; Baas et al., 1994) .
Previous studies addressing the prognostic value of p53 were mostly restricted to short-term follow-up, and in particular the IHC studies yielded variable results (Table IV) . This variability might come from several causes. First of all, these study groups may not always be comparable. Moreover, the use of various antibodies against different epitopes of the p53 protein, and sometimes the use of antigen retrieval systems, may also account for some of the variability in the percentages of p53 positivity seen among the different studies (Table IV) (van den Berg et al., 1993; reviewed in WynfordThomas, 1992; Hall and Lane, 1994) . We previously evaluated various procedures and six different p53 antibodies in relationship with underlying p53 changes and selected the two most accurate procedures for p53 protein detection for use in this study (Baas et al., 1994) . Objective quantification of p53 expression was achieved by use of a computerised image analyser. Opfimised IHC techniques combined with computerised quantification yielded p53 positivity in 72% of the carcinomas (Table I) , a percentage that exceeds that of all previous studies (Table IV) .
In our study, p53 expression was higher in metastatic carcinomas (LI = 37%) than in non-metastatic Dukes' B carcinomas (LI = 21%). However, this phenomenon is not consistently observed in other studies (Campo et al., 1991; Scott et al., 1992; Purdie et al., 1991; Remvikos et al., 1992; Starzynska et al., 1992; Sun et al., 1992; Bell et al., 1993; de Angelis et al., 1993; Bosari et al., 1994; Mulder et al., 1995) . As in other studies (Campo et al., 1991; Hanski et al., 1992) , mucinous carcinomas exhibited significntly less p53 protein than non-mucinous carcinomas, suggesting more p53 mutations in non-mucinous carcinomas. Together with other molecular aspects (Kern et al., 1989; Laurent-Puig et al., 1991) and similar findings in the ovary (Enomoto et al., 1991) , this finding suggests that mucinous tumours may be biologically different. No correlation was found between p53 expression and the other histopathological parameters. In this study, we did not observe a difference in p53 positivity between right-and left-sided carcinomas. This contrasts with some studies in which p53-positive tumours were predominantly found in the distal part of the large bowel (Scott et al., 1991; Remvikos et al., 1992; Starzynska et al., 1992; Bosari et al., 1994) , but is concordant with other studies (Purdie et al., 1991; Hansii et al., 1992; Yamaguchi et al., 1992; Bell et al., 1993; Nathanson et al., 1994) . (1994) and Sun et al. (1992) found cytoplasmic p53 staining with PAb CM1 to be of independent prognostic importance, but as in most other studies no reliable cytoplasmic staining was found in our study.
The lack of consistent prognostic value of nuclear p53 protein expression might indicate that the reported importance for prognosis of p53 mutation needs additional study and/or that the relationship between immunostaining of p53 protein and p53 gene mutation might be too much confounded by other biological mechanisms and technical caveats (reviewed in Wynford-Thomas, 1992; Hall and Lane, 1994) .
In conclusion, this study indicates that, with current methodology, p53 protein expression does not appear to contribute to the prediction of long-term prognosis after resection of colorectal carcinoma. We emphasise that further insight into the relationship between p53 gene mutations and p53 protein expression is needed to elucidate more precisely their clinical relevance.
